Skip to content
AACR 2025 logo

AACR 2025

14 interviews3 hr 4 min

American Association for Cancer Research Annual Meeting

Interviews and expert commentary from AACR 2025 — study authors and key opinion leaders discuss the findings and their clinical implications.

Patients with Relapsed or Refractory Acute Myeloid Leukemia have Remissions with “Logic Gated”  Off-the-Shelf Natural Killer Cell Therapy

Patients with Relapsed or Refractory Acute Myeloid Leukemia have Remissions with “Logic Gated”  Off-the-Shelf Natural Killer Cell Therapy

An Interview with: Stephen Strickland, Jr. MD MSCI, Director, Leukemia Research; Executive Chair, Leukemia Research Committee, Sarah Cannon Research Instiute, Nashville, Tennessee USA CHICAGO – Severa

8 May 2025
14 min
More Breast Cancer Cases in Younger Women since 2010 But Fewer Deaths

More Breast Cancer Cases in Younger Women since 2010 But Fewer Deaths

An interview with: Adetunji T. Toriola, MD, PhD, MPH, Professor of Surgery, Department of Surgery and Division of Public Health Sciences, Washington University School of Medicine and Siteman Cancer Ce

7 May 2025
15 min
Fast, Accurate Artificial Intelligence Method to Diagnose and Classify Pediatric Sarcoma Anywhere

Fast, Accurate Artificial Intelligence Method to Diagnose and Classify Pediatric Sarcoma Anywhere

An interview with: Adam Thiesen, PhD Candidate, UConn Health, University of Connecticut and the Jackson Laboratory for Genomic Medicine, Farmington,  CT And with: Jayesh Desai MD, Medical Oncologist,

6 May 2025
16 min
EGFR-Sparing Anti-HER2 Drug Benefits Patients with Advanced HER2-Mutated Non-Small Cell Lung Cancer

EGFR-Sparing Anti-HER2 Drug Benefits Patients with Advanced HER2-Mutated Non-Small Cell Lung Cancer

An interview with: John V Heymach MD PhD, Professor and Chair of Thoracic/Head and Neck Medical Oncology, Ruth Legett Jones Distinguished Chair, University of Texas MD Anderson Cancer Center, Houston

4 May 2025
13 min
Neoadjuvant PD-1 Blockade Enables Patients with Mismatch Repair Deficient Colorectal Cancers to Avoid Surgery

Neoadjuvant PD-1 Blockade Enables Patients with Mismatch Repair Deficient Colorectal Cancers to Avoid Surgery

An interview with: Andrea Cercek MD, Gastrointestinal Cancer Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York And: Ryan B Corcoran MD PhD, Director of the GI Cancer Program, Massac

3 May 2025
14 min
Topical BRAF-inhibiting Gel Controls Acneiform Rash in Patients with Colorectal Cancer Treated with EGFR-inhibition

Topical BRAF-inhibiting Gel Controls Acneiform Rash in Patients with Colorectal Cancer Treated with EGFR-inhibition

An interview with: Anisha B Patel MD, Associate Professor of Dermatology, Division of Internal Medicine, MD Anderson Cancer Center, Houston TX CHICAGO, USA—Acneiform rash toxicities caused by anti- ep

2 May 2025
9 min
RAS Inhibitor Zoldonrasib Brings Clinical Benefit in Patients with G12D Mutated Non-Small Cell Advanced Lung Cancer

RAS Inhibitor Zoldonrasib Brings Clinical Benefit in Patients with G12D Mutated Non-Small Cell Advanced Lung Cancer

An interview with: Kathryn C Arbour MD, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York USA And: Ryan B Corcoran MD PhD, Massachusetts General Cancer Center, Associate Pr

30 April 2025
12 min
Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab

Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab

Audio Journal of Oncology Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab LOS ANGELES, CA—Single agent immunotherapy with the anti-programmed death-1 (PD-

11 March 2025
14 min